GlobeNewswire by notified

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Share

Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa

  • Early customers include GP offices and other community-based healthcare settings
  • Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly half are undiagnosed1
  • The LumiraDx HbA1c test is designed to address the growing clinical need for accessible and reliable HbA1c testing in community-based healthcare settings such as primary care, diabetes clinics, rural clinics, retail pharmacy & other decentralised healthcare settings
  • The actively controlled microfluidic immunoassay is run on the highly portable LumiraDx Platform and designed for near-patient testing with connected results in under seven minutes
  • The addition of HbA1c to the rapidly growing LumiraDx test menu, enables the consolidation of multiple instruments to a single, next-generation point of care Platform; all with a common workflow

LONDON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings. Used alongside the LumiraDx Platform, the test monitors known diabetic patients’ HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes. Providing results in under seven minutes from sample application, the test allows improved efficiency and convenience with on-the-spot diabetes screening and monitoring at the patient’s side. The company announced the assay had achieved CE marking in late May of this year.

Today’s announcement comes on the heels of today’s World Diabetes Day which called attention to recent figures from the IDF Diabetes Atlas that 1 in 10 adults now have diabetes and nearly 1 in 2 are undiagnosed. 1 The portability and flexibility of the LumiraDx Platform enables the LumiraDx HbA1c test to address the growing clinical need for accessible and reliable HbA1c testing in the community healthcare setting to aid in quicker clinical decision making. The LumiraDx HbA1c test has a reportable range of 20 - 130 mmol/mol HbA1c (4.0 - 14.0% HbA1c). In an external, multi-site clinical study, the test achieved precision, expressed as mean paired replicate %CV, of ≤2.50% (NGSP) in both capillary and venous whole blood.

David Walton, LumiraDx’s Chief Commercial Officer commented, “As the global prevalence of diabetes is increasing, it’s critical for healthcare professionals to have access to rapid and reliable HbA1c results. The availability of an immediate, lab-comparable HbA1c test has been shown to improve patient outcomes through improved diabetes management. 2,3 In addition, there are a number of well-known comorbidities associated with diabetes. These are supported through our multi-assay testing Platform - including tests for cardiac biomarkers, coagulation, and inflammation- making the LumiraDx Platform an ideal tool for improving patient outcomes within the community healthcare setting.”

Professor Garry John, Consultant Clinical Biochemist, Norfolk and Norwich University Hospital, current Secretary of the IFCC Executive Committee of the Scientific Division (SD) and former Chairperson of the IFCC Working Group for the Global Standardisation of HbA1c, Honorary Professor, Norwich Medical School (UEA), explained, “Decentralised diabetes testing allows people to go to their GP or pharmacy and have these tests done there. This is important because it allows individuals to see their results immediately and therefore encourages them to achieve the target set out for them. It also enables the healthcare provider to be reassured that the level of improvement or control is a true representation of the metabolic situation.” He continued, “Basic laboratory support for clinical colleagues providing healthcare is fundamental; anything that allows our clinical teams to gather the complete information they need on the patient they are dealing with at that point in time is central to good metabolic control.”

Johannes Pachler, Managing Director of Leupamed Medizintechnik GmbH, a leading medical equipment supplier in Austria, commented, “The HbA1c test is a welcome addition to the LumiraDx Platform for our customers, which includes more than 100 LumiraDx Platforms used by GPs and internal medicine groups. We know there is tremendous value for clinicians being able to share immediate results with patients - this is particularly true for the monitoring and screening of diabetes. The intuitive nature of the Platform and the accurate results of the HbA1c test make it an important tool for diabetes management and clinicians are already seeing the positive impact the test can make on patient care.”

About LumiraDx
LumiraDx Limited (Nasdaq: LMDX) is next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.

The company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in the pipeline, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations. 

Founded in 2014 and based in the UK, LumiraDx’s diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease.

More information on LumiraDx is available at www.lumiradx.com. 

References:
1: worlddiabetesday.org/about/facts-figures/
2: diabetesjournals.org/care/article/22/11/1785/19794/Immediate-feedback-of-HbA1c-levels-improves
3. www.ncbi.nlm.nih.gov/pmc/articles/PMC4933534/

Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com
+1.917.344.9360

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e24265c7-f665-478a-92bd-b0f8f1bf9b53

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5%8.12.2022 19:00:00 CET | Press release

Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5% Nokia Corporation Stock Exchange Release 8 December 2022 at 20:00 EET Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5% According to a notification received under Chapter 9, Section 5 of the Finnish Securities Market Act (FSMA) by Nokia Corporation, the direct and indirect holdings of The Goldman Sachs Group, Inc. in Nokia have on 2 December 2022 exceeded 5% of the total number of shares and voting rights of Nokia. According to the notification received by Nokia, the holdings of The Goldman Sachs Group, Inc. in Nokia on 2 December 2022, directly and through its controlled undertakings and funds was equivalent to a total of 293,966,891 shares, corresponding to approximately 5.22% of the total number of shares and voting rights of Nok

Grant of Warrants8.12.2022 18:47:01 CET | Press release

December8, 2022 Announcement no. 18 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, December 8, 2022, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has, in accordance with its current authorization to issue warrants to key employees of BioPorto, today issued 1,200,000 warrants for the subscription of an equal number of shares. The warrants are issued in accordance with the Company’s remuneration policy and the authorization in section 18 a of the Articles of Association. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 2.55 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants vest over a four-year period. The warrants include conditions on claw-back in case of e.g., erroneous financial information and provisions on accelerated vesting in case of e.g., a takeover bid and/or business combinations. Detailed terms of the new and existing warr

Volta Finance Limited - Dividend Declaration8.12.2022 18:15:00 CET | Press release

Volta FinanceLimited (VTA/VTAS) Dividend Declaration NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 8 December 2022 Volta Finance Limited ("the Company") hereby announces a fourth interim dividend for the financial year commencing 1 August 2021. The Company announces that it has declared a quarterly interim dividend of €0.12 per share payable on 26 January 2023 amounting to approximately €4.42 million, equating approximately to an annualised 8% of net asset value. The ex-dividend date is 29 December 2022 with a record date of 30 December 2022. The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling. Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling. Such instructions may be given to Com

Ilkka Oyj – Acquisition of own shares on 8 December 20228.12.2022 18:00:00 CET | Press release

ILKKA OYJ, STOCK EXCHANGE RELEASE, 8 December 2022 at 19:00 EET IlkkaOyj – Acquisition of own shares on 8 December 2022 At Nasdaq Helsinki Ltd: Date8 December 2022Exchange transactionBuyShare trading codeILKKA2Amount, shares 1,400Average price/share, EUR3.6440Total cost, EUR5,101.60 The company holds a total of 4,317 of its own shares (ILKKA2) including the shares acquired on 8 December 2022. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Ilkka Oyj DANSKE BANK A/S, FINLAND BRANCH Jonathan Nyberg Antti Väliaho Additional information Olli Pirhonen, CEO, Ilkka Oyj, tel. +358 40 766 5418 www.ilkka.com Attachment Ilkka buyback 8.12.2022

KBC Group: Publication of transparency notification(s) received by KBC Group NV8.12.2022 18:00:00 CET | Press release

Press release Outside trading hours – Regulated information* Brussels, 8 December 2022, 18h00 Publication of transparency notification(s) received by KBC Group NV (art. 14, 1st section of the Act of 2 May 2007 concerning the disclosure of significant participations) Summary of the notification(s) KBC Group NV has received a transparency notification on 5 December 2022, which states that BlackRock Inc. had the following percentage of voting rights (for voting securities and financial instruments that are treated as equivalent to voting securities) in KBC Group: 4.95% dd. 1 December 2022. Content of the notification(s) The notification(s) contain(s) following information: Reason for the notification(s): acquisition or disposal of voting securities or voting rights or financial instruments that are treated as voting securitiesNotification(s) by: BlackRock Inc.Persons subject to the notification requirement: see annexesDate(s) on which the threshold is crossed: 1 December 2022.Threshold th